Takeda gains rights to ImmunoGen's antibody-drug conjugate technology

Published: 24-Mar-2015
Research & Development

ImmunoGen will receive upfront payment of US$20m, with potential for additional milestone payments of $210m


Japanese pharmaceutical company Takeda has gained the rights to ImmunoGen's antibody-drug conjugate (ADC) technology, including the US biotechnology company's new DNA-acting IGN payload agents.

Takeda will develop and commercialise targeted anticancer therapeutics to up to two undisclosed targets. The agreement also provides the company with the option to take a licence for a third target for an additional upfront fee.

ImmunoGen, located in Waltham, MA will receive an upfront payment of US$20m from Takeda and for each target the company is eligible to receive milestone payments potentially totalling up to $210m plus royalties on the commercial net sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any ADC products resulting from this agreement.

'ADC technology is a critically important tool in addressing unmet needs in oncology,' said Christopher Claiborne, Head of the Oncology Drug Discovery Unit at Takeda. 'By partnering with ImmunoGen, we are able to leverage this important technology in Takeda's R&D programme and bring novel agents to the clinic.'

Takeda signed the agreement through its wholly owned subsidiary, Millennium Pharmaceuticals.

  • Companies:
  • Takeda
  • ImmunoGen Inc
See more

You may also like

Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

Read more
The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors

Trending Articles

  1. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Cresset creates new Vice President role to lead its AI strategy Dr Mutlu Dogruel joins from Microsoft, where he was responsible for empowering organisations to implement scalable AI solutions into their workflow
  5. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Research & Development

Takeda opens new drug research facility in California

The 165,000 sqft facility will play an important role in connecting research collaborators from a local to a global scale
Research & Development

Pharma giants join £9.5 million dementia drug discovery collaboration

Johnson & Johnson Innovation, Takeda and Evotec have joined The Dementia Consortium
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Research & Development

New approaches to treat psychiatric disorders

Cardiff University forms new drug discovery collaboration for psychiatric disorders
Research & Development

Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company
Subscribe now